- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05284916
Difference in Patterns of Liver Diseases Related Admissions After the Era of DAAS
Difference in Patterns of Liver Diseases Related Admissions in Sohag University Hospital After the Era of Direct Acting Antiviral Drugs
Liver disease accounts for approximately 2 million deaths per year worldwide, 1 million due to complications of cirrhosis and 1 million due to viral hepatitis and hepatocellular carcinoma Hepatitis is defined as inflammation of the liver that can result from a variety of causes such as heavy alcohol use, autoimmune, drugs, or toxins In the United States, the most common types of viral hepatitis are Hepatitis A, Hepatitis B, and Hepatitis C The other types of viral hepatitis are hepatitis D and E and are less frequently encountered Cirrhosis results from chronic liver disease, and is characterized by advanced fibrosis, scarring, and formation of regenerative nodules leading to architectural distortion.In the past cirrhosis was generally thought to be irreversible but recent studies have shown that treatments aimed at the underlying cause especially in earlier stages of the disease can improve or even reverse fibrosis Since its discovery, hepatitis C virus (HCV) has been a constant burden for global health, with 3 to 4 million new infections each year and an overall number of 130-170 million infected people in the world New direct acting antiviral regimens (DAA) have changed the landscape of treatment of chronic hepatitis C DAA provide important advantages, including higher efficacy, shorter duration of treatment and an optimal safety profile Place of the study in patient admitted to Tropical Medicine and Gastroenterology Department, Sohag University Hospital Type of the study The study will be conducted in two stages The first one is a retrospective collection of the data from patients records during the period from Feburary 2017 to January 2018 and the second stage will include agroup of patients that will be admitted to Tropical Medicine and Gastroenterology Department within 6months after protocol acceptance Study period duration of study will be 6months after protocol acceptance Inclusion criteria:
Patients diagnosed with liver diseases(acute hepatitis, chronic hepatitis, liver cirrhosis, HCC and others) depending on clinical evidence of stigmata of liver disease (e.g. jaundice ,ascites ,palmar erythema , spider navi , etc),laboratory data and ultra sonographic features Methods Complete History Taking Clinical ExaminationLaboratory Investigations Abdominal Ultrasonography
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Liver disease accounts for approximately 2 million deaths per year worldwide, 1 million due to complications of cirrhosis and 1 million due to viral hepatitis and hepatocellular carcinoma Hepatitis is defined as inflammation of the liver that can result from a variety of causes such as heavy alcohol use, autoimmune, drugs, or toxins In the United States, the most common types of viral hepatitis are Hepatitis A, Hepatitis B, and Hepatitis C The other types of viral hepatitis are hepatitis D and E and are less frequently encountered Cirrhosis results from chronic liver disease, and is characterized by advanced fibrosis, scarring, and formation of regenerative nodules leading to architectural distortion.In the past cirrhosis was generally thought to be irreversible but recent studies have shown that treatments aimed at the underlying cause especially in earlier stages of the disease can improve or even reverse fibrosis Since its discovery, hepatitis C virus (HCV) has been a constant burden for global health, with 3 to 4 million new infections each year and an overall number of 130-170 million infected people in the world New direct acting antiviral regimens (DAA) have changed the landscape of treatment of chronic hepatitis C DAA provide important advantages, including higher efficacy, shorter duration of treatment and an optimal safety profile Place of the study in patient admitted to Tropical Medicine and Gastroenterology Department, Sohag University Hospital Type of the study The study will be conducted in two stages The first one is a retrospective collection of the data from patients records during the period from Feburary 2017 to January 2018 and the second stage will include agroup of patients that will be admitted to Tropical Medicine and Gastroenterology Department within 6months after protocol acceptance Study period duration of study will be 6months after protocol acceptance Inclusion criteria:
Patients diagnosed with liver diseases(acute hepatitis, chronic hepatitis, liver cirrhosis, HCC and others) depending on clinical evidence of stigmata of liver disease,laboratory data and ultra sonographic features Methods Complete History Taking Clinical ExaminationLaboratory Investigations Abdominal Ultrasonography
Studietype
Registrering (Forventet)
Kontakter og plasseringer
Studiekontakt
- Navn: momena H Ahmed, master
- Telefonnummer: 01060178232
- E-post: moamenahassn@med.sohag.edu.eg
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
- Eldre voksen
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Patients diagnosed with liver diseases depending on clinical evidence of stigmata of liver disease laboratory data and ultra sonographic features
Exclusion Criteria:
- Any patient without liver disease
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
---|---|
patients admitted at Sohag University Hospital diagnosed with liver diseases
The study will be conducted in two stages.
The first one is a retrospective collection of the data from patients records during the period from Feburary 2017 to January 2018 and the second stage will include agroup of patients that will be admitted to Tropical Medicine and Gastroenterology Department within 6months after protocol acceptance
|
The different patterns of liver disease related admissions after the era of DAAS
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
The different patterns of liver disease in patients admitted to Sohag University Hospital after the era of direct acting antiviral drugs
Tidsramme: from 15 March 2022 to 15 September 2022
|
from 15 March 2022 to 15 September 2022
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: momena H Ahmed, master, Sohag University
- Studieleder: Mona M Abdelrahman, MD, Sohag University
- Studiestol: Asmaa N Mohammed, MD, Sohag University
Studierekorddatoer
Studer hoveddatoer
Studiestart (Forventet)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- Soh-Med-22-03-09
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på liver diseases admissions
-
University of VirginiaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)FullførtDiabetes mellitus, type 1Forente stater
-
Atos Medical ABRoyal Brisbane and Women's Hospital; Princess Alexandra Hospital, Brisbane... og andre samarbeidspartnereFullført
-
Baylor College of MedicineFullført
-
Heidelberg UniversityGerman Federal Ministry of Education and Research; University of Ulm; Universitätsklinikum... og andre samarbeidspartnereFullførtTrening | FallforebyggingTyskland
-
University of Kansas Medical CenterFullført
-
Atos Medical ABInstituto de Cancer Dr ArnaldoHar ikke rekruttert ennå
-
Atos Medical ABFondazione Policlinico Universitario Agostino Gemelli IRCCSFullført
-
University of MichiganNational Institute of Nursing Research (NINR)FullførtKronisk obstruktiv lungesykdomForente stater
-
SK Plasma Co., Ltd.FullførtImmun trombocytopeniKorea, Republikken
-
Norwegian University of Science and TechnologyUniversity of Bologna; University of Manchester; VU University of Amsterdam; Ecole Polytechnique Fédérale de Lausanne og andre samarbeidspartnereFullførtUnge eldre voksneTyskland, Nederland, Norge